IDEXX Laboratories, Inc. (IDXX) updated its 2025 EPS outlook range to $12.81 - $13.01, incorporating a $0.33 increase at midpoint from prior guidance, reflecting $0.22 benefit from operational performance, $0.04 benefit from lower effective tax rate, net of impacts related to recent U.S. tax law changes, and approximately $0.07 combined benefit from updated estimates for interest expense, average shares outstanding, and foreign exchange impacts. The updated EPS growth outlook is 20% - 22% as reported and 12% - 14% on a comparable basis.
The company updated full year revenue growth guidance range to $4.27 billion - $4.30 billion, or reported growth of 9.6% - 10.3%, an increase of $43 million at midpoint. The company increased outlook for organic revenue growth to 8.8% - 9.5%, an increase of approximately 1% at midpoint.
For the third quarter, The company's earnings totaled $274.61 million, or $3.40 per share. This compares with $232.84 million, or $2.80 per share, last year. Comparable EPS was $3.22 compared to $2.79. Analysts on average had expected the company to earn $3.14 per share. Analysts' estimates typically exclude special items. Revenue rose 13.3% to $1.105 billion from $975.54 million last year.
Shares of IDEXX are up 5% in pre-market trade on Monday.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.